tbuckley/cabot-search huggingface dataset:
Diethyldithiocarbamate-copper nanocomplex reinforces disulfiram chemotherapeutic efficacy through light-triggered nuclear targeting
Authors: Liting Ren, Wenya Feng, Jie Shao, Juan Ma, Ming Xu, Ben-Zhan Zhu, Nanfeng Zheng, Sijin Liu
Journal: Theranostics (2020)

To circumvent the huge cost, long R&D time and the difficulty to identify the targets of new drugs, repurposing the ones that have been clinically approved has been considered as a viable strategy to treat different diseases.In the current study, we outlined the rationale for repurposing disulfiram (DSF, an old alcohol-aversion drug) to treat primary breast cancer and its metastases.Methods: To overcome a few shortcomings of the individual administration of DSF, such as the dependence on copper ions (Cu 2+ ) and limited capability in selective targeting, we here artificially synthesized the active form of DSF, diethyldithiocarbamate (DTC)-Cu complex (CuET) for cancer therapeutics.To achieve a greater efficacy in vivo, smart nanomedicines were devised through a one-step self-assembly of three functional components including a chemically stable and biocompatible phase-change material (PCM), the robust anticancer drug (CuET) and a near-infrared (NIR) dye (DIR), namely CuET/DIR NPs.A number of in vitro assays were performed including the photothermal efficacy, light-triggered drug release behavior, nuclear localization, DNA damage and induction of apoptosis of CuET/DIR NPs and molecular mechanisms underlying CuET-induced repression on cancer metastatic behaviors.Meanwhile, the mice bearing 4T1-LG12-drived orthotopic tumors were employed to evaluate in vivo biodistribution and anti-tumor effect of CuET/DIR NPs.The intravenous injection model was employed to reflect the changes of the intrinsic metastatic propensity of 4T1-LG12 cells responding to CuET/DIR NPs. Results:The rationally designed nanomedicines have self-traceability for bioimaging, long blood circulation time for enhanced drug accumulation in the tumor site and photo-responsive release of the anticancer drugs.Moreover, our data unearthed that CuET/DIR nanomedicines behave like "Trojan horse" to transport CuET into the cytoplasm, realizing substantial intracellular accumulation.Upon NIR laser irradiation, massive CuET would be triggered to release from the nanomedicines and reach a high local concentration towards the nucleus, where the pro-apoptotic effects were conducted.Importantly, our CuET/DIR nanomedicines revealed a pronounced capability to leash breast cancer metastases through inhibition on EMT.Additionally, these nanomedicines showed great biocompatibility in animals.Conclusion: These combined data unearthed a remarkably enhanced tumor-killing efficacy of our CuET nanomedicines through nuclear targeting.This work may open a new research area of repurposing DSF as innovative therapeutic agents to treat breast cancer and its metastases.
Cognitive Screening of Older Practitioners—Reply
Authors: Leo M. Cooney, Thomas Balcezak
Journal: JAMA (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Risk‐based, response‐adapted therapy for early‐stage extranodal nasal‐type <scp>NK</scp>/T‐cell lymphoma in the modern chemotherapy era: A China Lymphoma Collaborative Group study
Authors: Shu‐Nan Qi, Yong Yang, Yu‐Jing Zhang, Hui‐Qiang Huang, Ying Wang, Xia He, Li‐Ling Zhang, Gang Wu, Bao‐Lin Qu, Li‐Ting Qian, Xiao‐Rong Hou, Fu‐Quan Zhang, Xue‐Ying Qiao, Hua Wang, Gao‐Feng Li, Yuan Zhu, Jian‐Zhong Cao, Jun‐Xin Wu, Tao Wu, Su‐Yu Zhu, Mei Shi, Li‐Ming Xu, Zhi‐Yong Yuan, Hang Su, Yu‐Qin Song, Jun Zhu, Chen Hu, Ye‐Xiong Li
Journal: American Journal of Hematology (2020)

Abstract We aimed to determine the survival benefits of chemotherapy (CT) added to radiotherapy (RT) in different risk groups of patients with early‐stage extranodal nasal‐type NK/T‐cell lymphoma (ENKTCL), and to investigate the risk of postponing RT based on induction CT responses. A total of 1360 patients who received RT with or without new‐regimen CT from 20 institutions were retrospectively reviewed. The patients had received RT alone, RT followed by CT (RT + CT), or CT followed by RT (CT + RT). The patients were stratified into different risk groups using the nomogram‐revised risk index (NRI). A comparative study was performed using propensity score‐matched (PSM) analysis. Adding new‐regimen CT to RT (vs RT alone) significantly improved overall survival (OS, 73.2% vs 60.9%, P &lt; .001) and progression‐free survival (PFS, 63.5% vs 54.2%, P &lt; .001) for intermediate‐risk/high‐risk patients, but not for low‐risk patients. For intermediate‐risk/high‐risk patients, RT + CT and CT + RT resulted in non‐significantly different OS (77.7% vs 72.4%; P = .290) and PFS (67.1% vs 63.1%; P = .592). For patients with complete response (CR) after induction CT, initiation of RT within or beyond three cycles of CT resulted in similar OS (78.2% vs 81.7%, P = .915) and PFS (68.2% vs 69.9%, P = .519). For patients without CR, early RT resulted in better PFS (63.4% vs 47.6%, P = .019) than late RT. Risk‐based, response‐adapted therapy involving early RT combined with CT is a viable, effective strategy for intermediate‐risk/high‐risk early‐stage patients with ENKTCL in the modern treatment era.
Plumbagin-induced apoptosis in human prostate cancer cells is associated with modulation of cellular redox status and generation of reactive oxygen species
Authors: Anna Powolny, Shivendra Singh
Journal: Cancer Research (2008)

3830  Plumbagin (5-hydroxy-2-methyl-1, 4-naphthoquinone) occurs naturally in the herb Plumbago zeylanica L., which has been safely used for centuries in Indian Ayurvedic and traditional oriental medicine practices for the treatment of various ailments, including rheumatoid arthritis, acne, and microbial infections. Plumbagin has attracted a great deal of research interest due to its diverse pharmacological effects. The known pharmacological effects of plumbagin or Plumbago zeylanica extract include anti-leishmanial, anti-bacterial, anti-fungal, anti-allergic, hypolipidaemic, anti-atherosclerotic, and anticancer effects. For instance, dietary feeding of 200 ppm plumbagin decreased the incidence and multiplicity of azoxymethane-induced intestinal carcinogenesis in rats. We now demonstrate that plumbagin suppresses growth of cultured human prostate cancer cells (PC-3, LNCaP, and C4-2) irrespective of their androgen responsiveness or p53 status. The viability of each cell line was decreased significantly by treatment with plumbagin at pharmacologically relevant concentrations. Contrary to previous reports, plumbagin-mediated decrease in prostate cancer cell viability was not due to perturbations in cell cycle progression. Instead, plumbagin-mediated decrease in cell viability correlated with apoptosis induction characterized by appearance of sub-diploid apoptotic fraction and release of histone-associated DNA fragments into the cytosol. The plumbagin-induced apoptosis was associated with generation of reactive oxygen species (ROS) and depletion of intracellular glutathione levels. Pretreatment of cells with antioxidants inhibited plumbagin-mediated ROS generation as well as release of histone-associated DNA fragments into the cytosol. Plumbagin treatment also resulted in alteration of expression of genes responsible for ROS metabolism, including superoxide dismutase 2 (Mn-SOD) as revealed by RT2 Superarray analyses. Activity and protein levels of Mn-SOD were reduced by treatment with plumbagin in a dose-dependent manner. In conclusion, the present study reveals that the plumbagin-induced apoptosis in human prostate cancer cells is mediated by modulation of cellular redox status and ROS generation (supported in part by NCI grant CA115498).
Biodegradable Polymers as the Pivotal Player in the Design of Tissue Engineering Scaffolds
Authors: Fan Zhang, Martin W. King
Journal: Advanced Healthcare Materials (2020)

Abstract Biodegradable polymers play a pivotal role in in situ tissue engineering. Utilizing various technologies, researchers have been able to fabricate 3D tissue engineering scaffolds using biodegradable polymers. They serve as temporary templates, providing physical and biochemical signals to the cells and determining the successful outcome of tissue remodeling. Furthermore, a biodegradable scaffold also presents the fourth dimension for tissue engineering, namely time. The properties of the biodegradable polymer change over time, presenting continuously changing features during the degradation process. These changes become more complicated when different materials are combined together to fabricate a composite or heterogeneous scaffold. This review undertakes a systematic analysis of the basic characteristics of biodegradable polymers and describe recent advances in making composite biodegradable scaffolds for in situ tissue engineering and regenerative medicine. The interaction between implanted biodegradable biomaterials and the in vivo environment are also discussed, including the properties and functional changes of the degradable scaffold, the local effect of degradation on the contiguous tissue and their evaluation using both in vitro and in vivo models.
Prophylaxis for Stress-related Gastric Hemorrhage in the Medical Intensive Care Unit
Authors: Tamir Ben-Menachem, Ronald Fogel, Rakesh V. Patel, Mark Touchette, Barbara J. Zarowitz, Neven Hadzijahic, George Divine, Joel Verter, Robert S. Bresalier
Journal: Annals of Internal Medicine (1994)

Objective: To determine the efficacy and safety of cimetidine and sucralfate prophylaxis for stress-related gastrointestinal hemorrhage in patients admitted to a medical intensive care unit. Settin...
Response to: ‘Are patients with systemic lupus erythematosus at increased risk for COVID-19?’ by Favalli <i>et al</i>
Authors: Alexis Mathian, Zahir Amoura
Journal: Annals of the Rheumatic Diseases (2020)

We thank Favalli et al for their interest in our study reporting the course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease 2019 (COVID-19) in a case series of 17 patients with systemic lupus erythematosus (SLE) under long-term treatment with hydroxychloroquine (HCQ).1 2 As mentioned in our study, we did not aim at reporting the incidence rate and the severity of COVID-19 in SLE, because our cohort most likely over-represents the most symptomatic and severe cases, as a result of a bias in the selection procedure of the patients used by the physicians.

Favalli et al , by studying the nasopharyngeal carriage of SARS-CoV-2, confirm the low prevalence of COVID-19 in their cohort …
Long-Term Colorectal Cancer Incidence and Mortality After a Single Negative Screening Colonoscopy
Authors: Nastazja Dagny Pilonis, Marek Bugajski, Paulina Wieszczy, Robert Franczyk, Joanna Didkowska, Urszula Wojciechowska, Malgorzata Pisera, Maciej Rupinski, Jaroslaw Regula, Michal Filip Kaminski
Journal: Annals of Internal Medicine (2020)

Current guidelines recommend a 10-year interval between screening colonoscopies, but evidence is limited.To assess the long-term risk for colorectal cancer (CRC) and death from CRC after a high- and low-quality single negative screening colonoscopy.Observational study.Polish Colonoscopy Screening Program.Average-risk individuals aged 50 to 66 years who had a single negative colonoscopy (no neoplastic findings).Standardized incidence ratios (SIRs) and standardized mortality ratios (SMRs) of CRC after high- and low-quality single negative screening colonoscopy. High-quality colonoscopy included a complete examination, with adequate bowel preparation, performed by endoscopists with an adenoma detection rate of 20% or greater.Among 165 887 individuals followed for up to 17.4 years, CRC incidence (0.28 [95% CI, 0.25 to 0.30]) and mortality (0.19 [CI, 0.16 to 0.21]) were 72% and 81% lower, respectively, than in the general population. High-quality examination resulted in 2-fold lower CRC incidence (SIR, 0.16 [CI, 0.13 to 0.20]) and mortality (SMR, 0.10 [CI, 0.06 to 0.14]) than low-quality examination (SIR, 0.32 [CI, 0.29 to 0.35]; SMR, 0.22 [CI, 0.18 to 0.25]). In multivariable analysis, the hazard ratios for CRC incidence after high-quality versus low-quality colonoscopy were 0.55 (CI, 0.35 to 0.86) for 0 to 5 years, 0.54 (CI, 0.38 to 0.77) for 5.1 to 10 years, and 0.46 (CI, 0.25 to 0.86) for 10 to 17.4 years. Only after high-quality colonoscopy did the SIR and SMR for 10.1 to 17.4 years of follow-up not differ compared with earlier observation periods.The general population was used as the comparison group.A single negative screening colonoscopy was associated with reduced CRC incidence and mortality for up to 17.4 years. Only high-quality colonoscopy yielded profound and stable reductions in CRC incidence and mortality throughout the entire follow-up.Polish Ministry of Health.
Synthetic High-density Lipoprotein Nanodiscs for Personalized Immunotherapy Against Gliomas
Authors: Lindsay Scheetz, Padma Kadiyala, Xiaoqi Sun, Sejin Son, Alireza Hassani Najafabadi, Marisa Aikins, Pedro R. Lowenstein, Anna Schwendeman, Maria G. Castro, James J. Moon
Journal: Clinical Cancer Research (2020)

Gliomas are brain tumors with dismal prognoses. The standard-of-care treatments for gliomas include surgical resection, radiation, and temozolomide administration; however, they have been ineffective in providing significant increases in median survival. Antigen-specific cancer vaccines and immune checkpoint blockade may provide promising immunotherapeutic approaches for gliomas.
143P Quality of life (QoL) with palbociclib (PAL) plus endocrine therapy (ET) versus (vs) capecitabine (CAP) in luminal metastatic breast cancer (MBC) patients (pts) in the PEARL study
Authors: Z. Kahan, M. Gil-Gil, M. Ruiz-Borrego, E.M. Carrasco, E.M. Ciruelos, M. Muñoz, B. Bermejo De Las Heras, M. Margeli Vila, A. Anton, M. Casas, L. Calvo, J. de la Haba, M. Ramos, I. Álvarez-López, E. Gal-Yam, E. Gautier, M. Corsaro, G. Rodrigálvarez, C. Zielinski, M. Martin Jimenez
Journal: Annals of Oncology (2020)
Three Pictures, One Child
Authors: Mark B. Johnson
Journal: JAMA (1996)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Impact of antidiabetic agents on dementia risk: A Bayesian network meta-analysis
Authors: Jian-Bo Zhou, Xingyao Tang, Min Han, Jinkui Yang, Rafael Simó
Journal: Metabolism (2020)

BackgroundDementia is more prevalent among people with type 2 diabetes, but little is known regarding the influence of antidiabetic agents on this association.ObjectiveThis study assessed the impact of various antidiabetic agents on the risk of dementia among patients with Type 2 diabetes mellitus.MethodsRelevant studies were retrieved from the PubMed, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), and ClinicalTrials.gov databases. Nine antidiabetic agents were included in the search. Data were pooled via network meta-analysis and meta-analysis.ResultsNine studies were selected for the network meta-analysis with 530,355 individuals and 17 studies for the meta-analysis with 1,258,879 individuals. The analysis excluded glucagon-like peptide 1 (GLP-1) analogs and sodium-dependent glucose transporter 2 (SGLT-2) inhibitors due to the absence of relevant data. The use of dipeptidyl peptidase-4 (DPP-4) inhibitors, metformin, thiazolidinedione, and sulfonylurea was associated with a decreased risk of dementia in comparison to no treatment with antidiabetic agents (hazard ratio [HR] for DPP-4 inhibitors, 0.54; 95% confidence interval [CI], 0.38–0.74, HR for metformin, 0.75; 95% CI, 0.63–0.86; HR for sulfonylurea, 0.85; 95%CI, 0.73–0.98 and HR for thiazolidinedione, 0.70; 95% CI, 0.55–0.89, respectively). However, the node-splitting analysis showed the inconsistency of direct and indirect estimates in sulfonylurea (P = 0.042). DPP-4 inhibitors, metformin, thiazolidinedione, and sulfonylurea exhibited a significant impact on the risk of dementia in diabetics compared with insulin (HR, 0.35; 95%CI, 0.20–0.59, HR, 0.48; 95% CI, 0.30–0.77, HR, 0.45; 95% CI, 0.29–0.73 and HR, 0.55; 95% CI, 0.34–0.88, respectively). DPP-4 inhibitors also exhibited a protective effect on the risk of Alzheimer's dementia compared with the no treatment with antidiabetic agents (HR, 0.48; 95% CI, 0.25–0.92). The meta-analysis demonstrated a protective effect of using metformin and DPP-4 inhibitors on the risk of dementia (HR, 0.86; 95% CI, 0.74–1.00 and HR, 0.65; 95% CI, 0.55–0.76, respectively). Further analysis showed insulin was associated with an increased risk of Alzheimer's dementia (HR, 1.60; 95% CI, 1.13–2.26). Only two case-control studies mentioned GLP-1 analogs and SGLT-2 inhibitors, and the pooled ORs showed no evidence of an association with dementia (GLP-1 analogs: 0.71; 95% CI, 0.46–1.10 and SGLT-2 inhibitors: 0.74; 95% CI, 0.47–1.15).ConclusionThis analysis indicated that patients with type 2 diabetes under treatment with DPP-4 inhibitors presented with the lowest risk of dementia, followed by those treated with metformin and thiazolidinedione, while treatment with insulin was associated with the highest risk. For the increasing focus on the protective effect on dementia, further specific clinical studies are needed to evaluate the impact of GLP-1 analogs and SGLT-2 inhibitors on the risk of dementia.
33P Immune analysis of lymph nodes in relation to the presence or absence of tumour infiltrating lymphocytes in triple negative breast cancers
Authors: A. Quintana, V. Peg, T. Moline, A. Prat, L. Paré, P. Galván, G. Villacampa, R. Dientsmann, J. Perez, E. Muñoz, M. Martí, J. Blanco-Heredia, C. Dos Anjos, M. Vazquez, L. de Mattos, J. Cortés
Journal: Annals of Oncology (2020)
The Identification of High Risk APS Patients for Thrombosis with Triple Antiphospholipid Antibody Positivity Is Platform Dependent
Authors: Walid Chayouâ, Hilde Kelchtermans, Gary Moore, Jacek Musial, Denis Wahl, Stéphane Zuily, Armando Tripodi, Pierre Fontana, Jasper A. Remijn, Bas De Laat, Katrien Devreese
Journal: Blood (2017)
Abstract 20565: Risk Stratification of Acute Heart Failure Based on a Multi-Biomarker Analysis at Admission and Hospital Discharge
Authors: Jesús Álvarez-García, Álvaro García-Osuna, Andreu Ferrero-Gregori, Miquel Vives-Borrás, Grau-Agramunt Margarida, Eduard Solé-González, Miguel Rivera, Domingo Pascual-Figal, Luis Alonso-Pulpón, Francisco Fernández-Avilés, Delgado Juan, José Ramón González-Juanatey, Fernando Worner, Rafael Vázquez, Jordi Ordoñez-Llanos, Juan Cinca
Journal: Circulation (2017)

Introduction: Multi-biomarker strategies are a promising approach for enhancing the risk prediction in heart failure (HF). However, most previous studies have only evaluated these panels at a singl...
CLEVUDINE DEMONSTRATES POTENT ANTIVIRAL ACTIVITY IN LAMIVUDINE-EXPERIENCED PATIENTS
Authors: Heon-Ju Lee, Myung Sean Park, Dong Sung Kim, June Sung Lee, Jong Ho Park, Chang Hyeong Lee, Gob-Jin Cheon, Young-Oh Kweon, Won Young Tak, Byung Hoon Han, Sun Young Yi, Won Choong Choi, Sung-Kyu Choi, Nam Jae Kim, Su Yu Ahn
Journal: Hepatology (2018)
Inhibition of ubiquitin-specific protease 7 sensitizes acute myeloid leukemia to chemotherapy
Authors: Maëlle Cartel, Pierre-Luc Mouchel, Mathilde Gotanègre, Laure David, Sarah Bertoli, Véronique Mansat-De Mas, Arnaud Besson, Jean-Emmanuel Sarry, Stéphane Manenti, Christine Didier
Journal: Leukemia (2020)
Efficacy of face masks depends on spatial relation between host and recipient and who is being protected
Authors: Cliff Grover
Journal: BMJ (2020)

Discussion on whether face masks are effective often fails to differentiate between who is being protected, in what physical manner, and the spatial relation between host and recipient.1

When worn by the host, surgical masks or similar will reduce direct outward velocities of ejected droplets from a cough, sneeze, or ordinary out breathing and can help make velocities more uniform. Such a mask will also typically coalesce very small …
Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for NTRK fusion cancers
Authors: Tingting Jiang, Guan Wang, Yao Liu, Lu Feng, Meng Wang, Jie Liu, Yi Chen, Liang Ouyang
Journal: Acta Pharmaceutica Sinica B (2020)

Tropomyosin receptor kinase A, B and C (TRKA, TRKB and TRKC), which are well-known members of the cell surface receptor tyrosine kinase (RTK) family, are encoded by the neurotrophic receptor tyrosine kinase 1, 2 and 3 (NTRK1, NTRK2 and NTRK3) genes, respectively. TRKs can regulate cell proliferation, differentiation and even apoptosis through the RAS/MAPKs, PI3K/AKT and PLCγ pathways. Gene fusions involving NTRK act as oncogenic drivers of a broad diversity of adult and pediatric tumors, and TRKs have become promising antitumor targets. Therefore, achieving a comprehensive understanding of TRKs and relevant TRK inhibitors should be urgently pursued for the further development of novel TRK inhibitors for potential clinical applications. This review focuses on summarizing the biological functions of TRKs and NTRK fusion proteins, the development of small-molecule TRK inhibitors with different chemotypes and their activity and selectivity, and the potential therapeutic applications of these inhibitors for future cancer drug discovery efforts.
180TiP Palbociclib, trastuzumab and endocrine therapy (ET) versus treatment of physician's choice (TPC) in metastatic HER2-positive and hormone receptor-positive (HER2+/HR+) breast cancer (BC) with PAM50 luminal intrinsic subtype (SOLTI-1303 PATRICIA II): A randomized phase II trial
Authors: E.M. Ciruelos, P. Villagrasa, M. Oliveira, S. Pernas Simon, J. Cortés, S. Vazquez, N. Martínez, A. Perelló, B. Bermejo De Las Heras, E. Martínez, I. Garau Llinas, M. Mele Olive, A. Montaño, E. Vega, B. Cantos, M.J. Echarri, T. Pascual, P. Celiz, X. González-Farré, A. Prat
Journal: Annals of Oncology (2020)